Growing evidence has linked GLP-1 drugs to a reduced risk of exacerbations of asthma and COPD. Semaglutide was associated with a 38% reduction in exacerbations in asthma and 21% in COPD.
Lung Sask in collaboration with RESPTREC® offers the Professional Education Portal as a method for respiratory educators and health care providers to enhance their professional learning with continuing education opportunities.
Over 6000+ more articles available in the Professional Education Portal.
Read articles and watch video presentations on the most recent research, position papers and guidelines. Track your CE time with the provided logbook.